<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Radiation therapy of pituitary adenomas</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Radiation therapy of pituitary adenomas</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Radiation therapy of pituitary adenomas</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Helen A Shih, MD, MS, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Snyder, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 20, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H50913889"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pituitary adenomas are benign tumors that arise from the cells of the anterior pituitary gland. Primary treatment is usually surgery or pharmacologic treatment. When initial treatment with these interventions fails, or when there is a recurrence, radiation therapy should be considered.</p><p>Current radiation therapy employs more sophisticated imaging and targeting techniques than were previously available, but most published papers, which are based on retrospective series, report results using older techniques. The newer techniques offer the promise of reducing the incidence and severity of side effects. The relatively long time required for control of hormonal hypersecretion and the subsequent development of hypopituitarism have limited more widespread use of radiation therapy.</p><p>The common forms of radiation therapy for pituitary adenomas and their efficacy and side effects will be discussed here. More detailed discussions of pituitary adenoma treatment are found separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6631.html" rel="external">"Treatment of gonadotroph and other clinically nonfunctioning adenomas"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/174.html" rel="external">"Overview of the treatment of Cushing syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6630.html" rel="external">"Management of hyperprolactinemia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6625.html" rel="external">"Treatment of acromegaly"</a>.)</p><p></p><p class="headingAnchor" id="H50913897"><span class="h1">TYPES OF RADIATION THERAPY</span></p><p class="headingAnchor" id="H50913913"><span class="h2">Stereotactic radiosurgery (SRS)</span><span class="headingEndMark"> — </span>SRS is the delivery of a single high dose of radiation therapy using a high-precision localization system to treat a small target. It is most effective and safe when treating small sizes and when able to aim very accurately so that safety margins can be minimized and the total target size is as small as possible.</p><p class="headingAnchor" id="H50913928"><span class="h2">Fractionated radiation therapy</span><span class="headingEndMark"> — </span>Fractionated radiation therapy is the delivery of radiation therapy in multiple, small, daily doses, usually five days a week for five to six weeks. This is the most common way radiation therapy is delivered for most other indications of radiation treatment.</p><p>In deciding which form of radiation therapy should be employed for a particular pituitary adenoma, we consider these factors:</p><p class="headingAnchor" id="H27505744"><span class="h2">Treatment considerations</span><span class="headingEndMark"> — </span>Treatment schedule considerations for pituitary adenomas include:</p><p class="bulletIndent1"><span class="glyph">●</span>Convenience – SRS can be delivered as a single treatment, whereas fractionated radiation therapy requires 25 to 30 treatments.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Safety – Adenomas that are too close, 3 to 5 mm, to radiation-sensitive tissues, such as the optic chiasm or other parts of the optic pathway, are more safely treated with fractionated radiation therapy since a large, single dose of radiation to these tissues can cause blindness. Large adenomas, eg, 3 cm or greater in diameter, are also more safely treated with fractionated radiation because of the large volume of tissue receiving radiation. (See <a class="local">'Other damage'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Therapeutic response – Some studies report that SRS results in a more rapid reduction in elevated hormone concentrations than fractionated radiation treatment. However, these were not randomized trials, and there were differences between the populations receiving the two types of radiation [<a href="#rid1">1,2</a>]. Because SRS can cause damage to the optic pathways, the patients treated by a single large dose had smaller adenomas than those treated by fractionated doses [<a href="#rid1">1,2</a>].</p><p></p><p class="headingAnchor" id="H50913935"><span class="h1">RADIATION DELIVERY SYSTEMS</span></p><p class="headingAnchor" id="H50913943"><span class="h2">Gamma Knife</span><span class="headingEndMark"> — </span>Gamma Knife is a stereotactic radiosurgery (SRS) treatment unit that uses radioactive isotope cobalt-60 to deliver radiation. Much of the radiation treatment for pituitary adenomas was pioneered using Gamma Knife. The radioactive cobalt-60 is housed within the machine, which controls how the small beams of gamma rays, also known as photons, are directed. Patients are positioned within the unit with their head held in place by a metal frame. The machinery aims multiple tiny beams of radiation at the desired intracranial target. The greatest experience of SRS (single treatments) in the management of pituitary adenomas has been with Gamma Knife.</p><p>Treatments are typically limited to one visit because the head frame is attached with pins to the scalp that are minimally invasive but pierce the skin to fix on the skull. This localized trauma would not be considered appropriate to perform repeatedly, as it leaves a small wound mark at each pin site with each application. Dose delivery with a low energy source such as cobalt-60 requires a large dose gradient such that the dose delivered to the periphery of a target is approximately half the dose delivered to the geometric center of the target. There are over 200 angles arranged around the patient's head from which these small beams can be directed to the adenoma target. Not all beam sources are used. The choice of beams per target creates the conformal radiation treatment. Doses for each type of pituitary adenoma are described below and refer to the margin dose delivered to the target since this is the expected minimum therapeutic dose. The latest generation of this unit employs a noninvasive immobilization head frame, such that multiple fraction treatments are now feasible. (See <a class="local">'Efficacy and suggested approach'</a> below.)</p><p class="headingAnchor" id="H50913950"><span class="h2">Linear accelerator</span><span class="headingEndMark"> — </span>The linear accelerator is the most common device used to deliver radiation treatments, ie, it is the basic radiation therapy machine. It accelerates electrons to high speeds and then converts this energy to high-energy x-rays, also known as photons. Many technological modifications are used to deliver the radiation to the desired location and dose. Complex shapes can be treated, and the dose can be varied across the target. Terms that are sometimes used to denote types of fractionated radiation delivery using a linear accelerator include three-dimensional conformal therapy, intensity modulated radiation therapy, and fractionated stereotactic radiotherapy. A term describing a single large dose delivered from a linear accelerator can be called single fraction SRS. Both fractionated radiation therapy and single fraction SRS are common uses of the linear accelerator.</p><p class="headingAnchor" id="H50913957"><span class="h2">CyberKnife</span><span class="headingEndMark"> — </span>CyberKnife can deliver either a single large dose or fractionated therapy. It is a small linear accelerator mounted on a robotic arm. The arm has more freedom to move around patients than the radiation source in other delivery systems and, therefore, allows patients to be in less confining positions as the unit is able to more easily compensate for variations in the patient's daily position. Numerous small radiation beams are used to deliver the radiation to the desired location. The overall length of time of treatment on a CyberKnife is typically longer than with other radiation therapy modalities.</p><p class="headingAnchor" id="H50913964"><span class="h2">Proton therapy</span><span class="headingEndMark"> — </span>Proton therapy is delivery of high-energy proton particles most commonly generated by a cyclotron or synchrotron. Proton therapy results in less exposure of the surrounding normal tissue to an excess dose than do photon-based modalities. The decrease in the collateral unintended radiation exposure of normal tissues may decrease side effects from treatment. The number of proton therapy facilities has been scarce because of the complexity and capital cost of these centers but is increasing, with approximately 40 centers open in 2021 as compared with 2 centers in 2000.</p><p class="headingAnchor" id="H50913971"><span class="h1">EFFICACY AND SUGGESTED APPROACH</span><span class="headingEndMark"> — </span>The relatively slow response of hypersecretion to radiation therapy, compared with surgery and even with pharmacologic treatment, is a disadvantage of this technique. Control of adenoma growth, however, is very high using all of the techniques.</p><p>There has been extensive experience with use of all forms of radiation therapy for pituitary adenomas, but individual published reports generally describe retrospective experiences using a single technique. As a consequence, it is difficult to compare the results of the various techniques, especially in controlling excessive secretion of pituitary hormones. The difficulty is compounded by the use of different radiation doses and different biochemical criteria for cure of hypersecretion [<a href="#rid3">3</a>].</p><p>The effect of adenoma size and concomitant pharmacologic treatment for hormonal hypersecretion on the response to Gamma Knife treatment has been reported in 418 patients with mixed types of pituitary adenomas [<a href="#rid4">4</a>], 40 patients with Cushing's disease [<a href="#rid5">5</a>], and 46 patients with acromegaly [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Adenoma size – Larger adenoma volume was associated with a lower rate of hormonal control in one study [<a href="#rid5">5</a>] and greater rate of new hormonal deficiencies in another [<a href="#rid4">4</a>] but was not associated with a differential effect on adenoma size in two studies [<a href="#rid4">4,6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concomitant pharmacologic treatment – Pharmacologic treatment (somatostatin analogs for acromegaly and dopamine agonists for lactotroph adenomas) at the time of irradiation was associated with lower rates of hormonal control [<a href="#rid4">4</a>] and a higher incidence of hypopituitarism [<a href="#rid4">4</a>] but no difference in control of adenoma size [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1">These associations are difficult to interpret, however, because concomitant pharmacologic treatment of patients with Cushing's disease with <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a>, which blocks cortisol synthesis in the adrenal glands, ie, does not affect the pituitary gland, also reduces the hormonal efficacy of Gamma Knife treatment [<a href="#rid5">5</a>]. This observation suggests that the more favorable effect of radiation when pharmacologic treatment has been withheld is related to another factor, eg, selection bias, and not to a direct effect of the drug on the pituitary adenoma.</p><p></p><p class="headingAnchor" id="H50913979"><span class="h2">Clinically nonfunctioning pituitary adenomas</span><span class="headingEndMark"> — </span>Radiation therapy is considered for clinically nonfunctioning adenomas:</p><p class="bulletIndent1"><span class="glyph">●</span>When residual adenoma remains after surgery. The rationale is that continued growth is approximately 30 to 60 percent at five years when obvious adenoma tissue, as detected by magnetic resonance imaging (MRI), remains after surgery [<a href="#rid7">7-9</a>]. Residual tumor outside the sella is associated with a higher rate of progression than residual adenoma limited to within the sella [<a href="#rid7">7,10,11</a>]. Alternatively, the residual adenoma can be monitored, and the potential side effects of radiation therapy can be avoided entirely in those patients in which the residual adenoma never progresses or at least postponed. (See  <a class="medical medical_review" href="/d/html/6631.html" rel="external">"Treatment of gonadotroph and other clinically nonfunctioning adenomas", section on 'Residual adenoma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When residual adenoma regrows following surgery. In this setting, radiation therapy is an alternative to repeat surgery. (See  <a class="medical medical_review" href="/d/html/6631.html" rel="external">"Treatment of gonadotroph and other clinically nonfunctioning adenomas"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recurrence of the adenoma when no residual adenoma is seen by MRI is as low as &lt;5 percent at five years or up to 10 to 25 percent at 10 years [<a href="#rid7">7,8,11-13</a>]. When no or little adenoma tissue is apparent after surgery, radiation is not recommended, only observation. (See  <a class="medical medical_review" href="/d/html/6631.html" rel="external">"Treatment of gonadotroph and other clinically nonfunctioning adenomas"</a>.)</p><p></p><p>The goal of radiation therapy in this setting is to stop adenoma growth. Shrinkage, partly or completely, may occur but is not necessary to consider the treatment a success [<a href="#rid14">14,15</a>].</p><p>The type of radiation depends on the proximity of the residual adenoma tissue to the optic pathway and its size.</p><p class="bulletIndent1"><span class="glyph">●</span>Stereotactic radiosurgery (SRS) can be considered if the adenoma tissue is not within 3 to 5 mm of the optic pathway and is less than 3 cm in diameter. A common SRS dose is 18 to 20 Gy [<a href="#rid4">4,16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fractionated radiation therapy is generally chosen for adenoma tissue that is larger and/or closer to the optic pathway. The usual dose is 45 to 50.4 Gy at 1.8 Gy daily fractions [<a href="#rid17">17</a>].</p><p></p><p>Either form of radiation controls adenoma size in 90 percent of patients at 5 to 10 years [<a href="#rid4">4,16-18</a>]. (See  <a class="medical medical_review" href="/d/html/6631.html" rel="external">"Treatment of gonadotroph and other clinically nonfunctioning adenomas"</a>.)</p><p class="headingAnchor" id="H99556046"><span class="h2">Clinically functioning pituitary adenomas</span><span class="headingEndMark"> — </span>The goal of therapy with nonfunctioning pituitary adenomas is tumor growth control; in contrast, the goal of radiation for functioning pituitary adenomas is both tumor growth and biochemical control, which typically require higher radiation doses.</p><p class="headingAnchor" id="H50913986"><span class="h3">Corticotroph adenomas (Cushing's disease)</span><span class="headingEndMark"> — </span>Radiation treatment is considered for corticotroph adenomas causing Cushing's disease when surgery has been unsuccessful. The principal goal is to lower corticotropin (ACTH) secretion and thereby lower cortisol secretion to normal. (See  <a class="medical medical_review" href="/d/html/118.html" rel="external">"Primary therapy of Cushing disease: Transsphenoidal surgery and pituitary irradiation", section on 'Pituitary irradiation'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type of radiation</strong> – SRS (20 to 25 Gy) is considered the first choice if the adenoma is not close to the optic pathway; fractionated radiation (50.4 to 54 Gy) is used for those that are [<a href="#rid4">4,19-23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Reduction of cortisol to normal occurs in approximately 50 percent of subjects by two to five years and higher is projected with longer follow-up [<a href="#rid4">4,19,20,22,24</a>]. Normalization of cortisol may occur somewhat faster after SRS than fractionated therapy, a median of 7.5 to 33 months versus 18 to 42 months [<a href="#rid1">1</a>]. Efficacy appears similar among all forms of SRS: Gamma Knife [<a href="#rid20">20</a>], linear accelerator [<a href="#rid19">19</a>], and protons [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/d/html/174.html" rel="external">"Overview of the treatment of Cushing syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Control of adenoma growth</strong> – This is especially important in corticotroph macroadenomas. All modalities of radiation therapy control adenoma growth in 90 to 100 percent of patients [<a href="#rid4">4,19,20,22</a>], similar to nonfunctioning adenomas. (See <a class="local">'Clinically nonfunctioning pituitary adenomas'</a> above.)</p><p></p><p>Corticotroph adenomas associated with Nelson syndrome may be less responsive to radiation than other corticotroph adenomas, but the data are limited [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/16322.html" rel="external">"Persistent or recurrent Cushing disease: Surgical adrenalectomy", section on 'Nelson syndrome'</a>.)</p><p class="headingAnchor" id="H50914001"><span class="h3">Somatotroph adenomas (acromegaly)</span><span class="headingEndMark"> — </span>Radiation therapy is considered for treatment of acromegaly when surgery and pharmacologic therapy have been unsuccessful in controlling growth hormone secretion or, less commonly, adenoma growth. (See  <a class="medical medical_review" href="/d/html/6625.html" rel="external">"Treatment of acromegaly", section on 'Radiation therapy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>SRS and fractionated radiation appear to be equivalent for treatment of somatotroph adenomas. The usual doses of radiation are 20 to 25 Gy for SRS and 50.4 to 54 Gy for fractionated radiation therapy [<a href="#rid4">4,12,25-28</a>]. (See  <a class="medical medical_review" href="/d/html/6625.html" rel="external">"Treatment of acromegaly", section on 'Radiation therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All forms of SRS appear to be equivalent for efficacy. Most experience has been with Gamma Knife [<a href="#rid4">4,12,26</a>], but the results are similar with linear accelerator [<a href="#rid25">25</a>], CyberKnife [<a href="#rid29">29</a>], and proton therapy [<a href="#rid23">23</a>]. With all forms, reduction of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels to normal occurs relatively slowly: 50 to 60 percent response at 5 to 10 years and 65 to 87 percent at 15 years [<a href="#rid4">4,12,25-28</a>]. Patients with lower serum GH concentrations prior to radiation therapy appear to be more responsive to treatment [<a href="#rid27">27,30</a>]. Local control of tumor is high at 95 to 100 percent [<a href="#rid12">12,25,26,28</a>].</p><p></p><p class="headingAnchor" id="H50914016"><span class="h3">Lactotroph adenomas (prolactin-secreting adenomas)</span><span class="headingEndMark"> — </span>Because 90 percent of lactotroph adenomas respond to dopamine agonists and most of the rest can be treated successfully by surgery, the usual goal of radiation treatment is to control growth of a large adenoma when dopamine agonist treatment and surgery have not. Single-dose and multiple fraction radiation appear to be equally effective.</p><p class="bulletIndent1"><span class="glyph">●</span>Radiation therapy, either single dose [<a href="#rid25">25,31-33</a>] or multiple fractions [<a href="#rid17">17,18</a>], appears to be effective in controlling growth in up to 89 to 100 percent of patients in reported series. These reports, however, do not specifically describe the effect on the aggressive lactotroph adenoma that does not respond to dopamine agonist treatment and cannot be entirely resected surgically, which is the kind of adenoma for which radiation is needed most.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiation therapy results in highly variable effects on hyperprolactinemia, but overall up to 50 percent of patients have a return to normal prolactin level with radiation therapy alone though they generally require more years to respond than other types of functioning adenomas, and a majority are managed with the addition of a dopamine agonist [<a href="#rid4">4,17,34,35</a>]. Hyperprolactinemia, however, does not require correction if it is not causing hypogonadism and, if it is, can be managed by administration of gonadal steroids.</p><p></p><p class="headingAnchor" id="H50914030"><span class="h1">RISKS/ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>The risks of radiation therapy are development of new hypopituitarism, which is common, and neurologic damage and others, which are not.</p><p class="headingAnchor" id="H3432974"><span class="h2">Hypopituitarism</span><span class="headingEndMark"> — </span>Hypopituitarism occurs following both fractionated and single-dose radiation therapy.</p><p class="bulletIndent1"><span class="glyph">●</span>In two series of 385 and 884 patients treated with <strong>fractionated</strong> radiation therapy, new deficiencies of corticotropin (ACTH), thyroid-stimulating hormone (TSH), and gonadotropins occurred in approximately 20 percent of patients at five years and up to 30 percent at 10 years [<a href="#rid17">17,27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In two studies that included a total of 494 patients, 418 and 76 with mixed types of pituitary adenomas treated by <strong>single-dose</strong> radiation therapy (Gamma Knife), 21 to 24 percent developed one or more pituitary hormone deficiencies, mostly two to four years after radiation (the frequency of individual deficiencies was not described) [<a href="#rid4">4,32</a>]. The risk of hormonal deficiencies increases to as high as 80 percent by 10 to 15 years [<a href="#rid13">13,22</a>]. All patients undergoing sellar radiation therapy should be counseled on the high risk of hypopituitarism and the importance of neuroendocrine function surveillance.</p><p></p><p>The risk of hypopituitarism can sometimes be reduced with minimization of normal pituitary collateral irradiation, which may be possible with well-lateralized adenomas. Limiting the radiation to the hypothalamus may also reduce radiation-associated hypopituitarism [<a href="#rid36">36,37</a>]. The management of hypopituitarism is reviewed separately. (See  <a class="medical medical_review" href="/d/html/6640.html" rel="external">"Treatment of hypopituitarism"</a>.)</p><p class="headingAnchor" id="H3433383"><span class="h2">Other damage</span><span class="headingEndMark"> — </span>Other side effects of sellar irradiation are far less common:</p><p class="bulletIndent1"><span class="glyph">●</span>Optic pathway injury – In two series of 796 patients treated by <strong>fractionated</strong> radiation therapy, injury to the optic pathway was reported in 0.8 to 1.3 percent at 10 years and 1.5 percent at 20 years [<a href="#rid17">17,38</a>]. Risk is minimized if the dose is kept to 54 Gy or slightly less if there is preexisting injury to vision [<a href="#rid39">39-41</a>]. For <strong>single-dose</strong> radiation therapy, the risk of optic pathway injury is minimal if the dose to these structures is kept below 8 to 10 Gy but is approximately 1 percent at 12 Gy [<a href="#rid39">39,40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cranial nerve injury – This is uncommon but more likely to occur following re-irradiation [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Secondary tumors – The incidence was 1.9 percent at 20 years in two large studies [<a href="#rid17">17,38</a>], but the radiation delivery technique in those studies exposed a much larger volume of tissue to radiation than do current techniques.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Strokes – An increased risk of stroke has been observed in pituitary adenoma patients who have received radiation therapy. However, the risk appears to be due to their preexisting cardiovascular risk factors such as coronary disease and peripheral vascular disease and not the radiation therapy [<a href="#rid43">43</a>].</p><p></p><p class="headingAnchor" id="H1857381359"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112709.html" rel="external">"Society guideline links: Diagnosis and treatment of Cushing syndrome"</a> and  <a class="medical medical_society_guidelines" href="/d/html/116763.html" rel="external">"Society guideline links: Diagnosis and treatment of acromegaly"</a> and  <a class="medical medical_society_guidelines" href="/d/html/116762.html" rel="external">"Society guideline links: Pituitary tumors and hypopituitarism"</a>.)</p><p class="headingAnchor" id="H50914038"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Radiation therapy can be delivered using x-rays from a linear accelerator or CyberKnife, gamma radiation (Gamma Knife), or protons. Radiation can be delivered in a single large dose (stereotactic radiosurgery [SRS]) or multiple fractions (fractionated radiation therapy). (See <a class="local">'Types of radiation therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiation therapy of any kind controls adenoma volume in 90 to 100 percent of patients. Radiation therapy may also reduce hormonal hypersecretion, but the effect is variable and slow; complete normalization occurs in approximately 50 percent of patients after 10 years. (See <a class="local">'Efficacy and suggested approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiation therapy causes hypopituitarism in up to 80 percent of patients after 10 years but has very low risk of optic pathway and other long-term side effects. (See <a class="local">'Risks/adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest radiation therapy be administered to patients with pituitary adenomas only after surgical and/or medical options have been exhausted (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Risks/adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest SRS for adenomas that are not close to the optic pathway (at least 3 to 5 mm away) and are smaller than 3 cm in diameter and fractionated radiation therapy for adenomas that are larger than 3 cm and/or closer to the optic pathway (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Risks/adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For clinically <strong>nonfunctioning</strong> pituitary adenomas, we suggest either SRS or fractionated radiation therapy, depending upon the size and location of the adenoma. If SRS is chosen, we suggest a dose of 18 Gy (range 14 to 20 Gy) and no more than 8 to 10 Gy to the optic pathway. If fractionated radiation therapy is chosen, we suggest a dose of 45 to 50.4 Gy at 1.8 Gy per fraction and no more than 54 Gy to the optic pathway. The goal of therapy with nonfunctioning pituitary adenomas is tumor growth control. (See <a class="local">'Clinically nonfunctioning pituitary adenomas'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For clinically <strong>functioning</strong> (eg, secretory) pituitary adenomas, we suggest either SRS or fractionated radiation therapy, depending upon the size and location of the adenoma. If SRS is chosen, we suggest a dose of 20 Gy (range 20 to 25 Gy) and no more than 8 to 10 Gy to the optic pathway. If fractionated radiation therapy is chosen, we suggest a dose of 50.4 to 54 Gy at 1.8 Gy per fraction and no more than 54 Gy to the optic pathway. The goal of radiation therapy for functioning pituitary adenomas is both biochemical control, which typically requires higher radiation doses, and tumor growth control. (See <a class="local">'Clinically functioning pituitary adenomas'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients taking pharmacologic treatment to reduce hormonal secretion by the adenoma, eg, dopamine agonist or somatostatin analog, we suggest discontinuing it for one month prior to and one month following radiation treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Efficacy and suggested approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For all patients, we recommend counseling on the high risk of subsequent development of hypopituitarism and the importance of lifelong surveillance after treatment. (See <a class="local">'Risks/adverse effects'</a> above.)</p><p></p><p class="headingAnchor" id="H3136902676"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>We are saddened by the death of Jay Loeffler, MD, who passed away in June 2023. UpToDate acknowledges Dr. Loeffler's past work as an author for this topic.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mitsumori M, Shrieve DC, Alexander E 3rd, et al. Initial clinical results of LINAC-based stereotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys 1998; 42:573.</a></li><li><a class="nounderline abstract_t">Landolt AM, Haller D, Lomax N, et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg 1998; 88:1002.</a></li><li><a class="nounderline abstract_t">Sheehan JP, Niranjan A, Sheehan JM, et al. Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg 2005; 102:678.</a></li><li><a class="nounderline abstract_t">Sheehan JP, Pouratian N, Steiner L, et al. Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. J Neurosurg 2011; 114:303.</a></li><li><a class="nounderline abstract_t">Castinetti F, Nagai M, Dufour H, et al. Gamma knife radiosurgery is a successful adjunctive treatment in Cushing's disease. Eur J Endocrinol 2007; 156:91.</a></li><li><a class="nounderline abstract_t">Pollock BE, Jacob JT, Brown PD, Nippoldt TB. Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. J Neurosurg 2007; 106:833.</a></li><li><a class="nounderline abstract_t">Brochier S, Galland F, Kujas M, et al. Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur J Endocrinol 2010; 163:193.</a></li><li><a class="nounderline abstract_t">O'Sullivan EP, Woods C, Glynn N, et al. The natural history of surgically treated but radiotherapy-naïve nonfunctioning pituitary adenomas. Clin Endocrinol (Oxf) 2009; 71:709.</a></li><li><a class="nounderline abstract_t">Losa M, Mortini P, Barzaghi R, et al. Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg 2008; 108:525.</a></li><li><a class="nounderline abstract_t">Greenman Y, Ouaknine G, Veshchev I, et al. Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clin Endocrinol (Oxf) 2003; 58:763.</a></li><li><a class="nounderline abstract_t">Chang EF, Zada G, Kim S, et al. Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg 2008; 108:736.</a></li><li><a class="nounderline abstract_t">Losa M, Gioia L, Picozzi P, et al. The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma. J Clin Endocrinol Metab 2008; 93:2546.</a></li><li><a class="nounderline abstract_t">van den Bergh AC, van den Berg G, Schoorl MA, et al. Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy. Int J Radiat Oncol Biol Phys 2007; 67:863.</a></li><li><a class="nounderline abstract_t">Pollock BE, Cochran J, Natt N, et al. Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience. Int J Radiat Oncol Biol Phys 2008; 70:1325.</a></li><li><a class="nounderline abstract_t">Mingione V, Yen CP, Vance ML, et al. Gamma surgery in the treatment of nonsecretory pituitary macroadenoma. J Neurosurg 2006; 104:876.</a></li><li><a class="nounderline abstract_t">Liscák R, Vladyka V, Marek J, et al. Gamma knife radiosurgery for endocrine-inactive pituitary adenomas. Acta Neurochir (Wien) 2007; 149:999.</a></li><li><a class="nounderline abstract_t">Erridge SC, Conkey DS, Stockton D, et al. Radiotherapy for pituitary adenomas: long-term efficacy and toxicity. Radiother Oncol 2009; 93:597.</a></li><li><a class="nounderline abstract_t">Ronson BB, Schulte RW, Han KP, et al. Fractionated proton beam irradiation of pituitary adenomas. Int J Radiat Oncol Biol Phys 2006; 64:425.</a></li><li><a class="nounderline abstract_t">Devin JK, Allen GS, Cmelak AJ, et al. The efficacy of linear accelerator radiosurgery in the management of patients with Cushing's disease. Stereotact Funct Neurosurg 2004; 82:254.</a></li><li><a class="nounderline abstract_t">Jagannathan J, Sheehan JP, Pouratian N, et al. Gamma Knife surgery for Cushing's disease. J Neurosurg 2007; 106:980.</a></li><li><a class="nounderline abstract_t">Estrada J, Boronat M, Mielgo M, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med 1997; 336:172.</a></li><li><a class="nounderline abstract_t">Minniti G, Osti M, Jaffrain-Rea ML, et al. Long-term follow-up results of postoperative radiation therapy for Cushing's disease. J Neurooncol 2007; 84:79.</a></li><li><a class="nounderline abstract_t">Wattson DA, Tanguturi SK, Spiegel DY, et al. Outcomes of proton therapy for patients with functional pituitary adenomas. Int J Radiat Oncol Biol Phys 2014; 90:532.</a></li><li><a class="nounderline abstract_t">Loeffler JS, Shih HA. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 2011; 96:1992.</a></li><li><a class="nounderline abstract_t">Voges J, Kocher M, Runge M, et al. Linear accelerator radiosurgery for pituitary macroadenomas: a 7-year follow-up study. Cancer 2006; 107:1355.</a></li><li><a class="nounderline abstract_t">Jezková J, Marek J, Hána V, et al. Gamma knife radiosurgery for acromegaly--long-term experience. Clin Endocrinol (Oxf) 2006; 64:588.</a></li><li><a class="nounderline abstract_t">Jenkins PJ, Bates P, Carson MN, et al. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 2006; 91:1239.</a></li><li><a class="nounderline abstract_t">Jallad RS, Musolino NR, Salgado LR, Bronstein MD. Treatment of acromegaly: is there still a place for radiotherapy? Pituitary 2007; 10:53.</a></li><li><a class="nounderline abstract_t">Roberts BK, Ouyang DL, Lad SP, et al. Efficacy and safety of CyberKnife radiosurgery for acromegaly. Pituitary 2007; 10:19.</a></li><li><a class="nounderline abstract_t">Barrande G, Pittino-Lungo M, Coste J, et al. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 2000; 85:3779.</a></li><li><a class="nounderline abstract_t">Pouratian N, Sheehan J, Jagannathan J, et al. Gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery 2006; 59:255.</a></li><li><a class="nounderline abstract_t">Castinetti F, Nagai M, Morange I, et al. Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab 2009; 94:3400.</a></li><li><a class="nounderline abstract_t">Jezková J, Hána V, Krsek M, et al. Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clin Endocrinol (Oxf) 2009; 70:732.</a></li><li><a class="nounderline abstract_t">Pan L, Zhang N, Wang EM, et al. Gamma knife radiosurgery as a primary treatment for prolactinomas. J Neurosurg 2000; 93 Suppl 3:10.</a></li><li><a class="nounderline abstract_t">Tsang RW, Brierley JD, Panzarella T, et al. Role of radiation therapy in clinical hormonally-active pituitary adenomas. Radiother Oncol 1996; 41:45.</a></li><li><a class="nounderline abstract_t">Pai HH, Thornton A, Katznelson L, et al. Hypothalamic/pituitary function following high-dose conformal radiotherapy to the base of skull: demonstration of a dose-effect relationship using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2001; 49:1079.</a></li><li><a class="nounderline abstract_t">Leenstra JL, Tanaka S, Kline RW, et al. Factors associated with endocrine deficits after stereotactic radiosurgery of pituitary adenomas. Neurosurgery 2010; 67:27.</a></li><li><a class="nounderline abstract_t">Brada M, Rajan B, Traish D, et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf) 1993; 38:571.</a></li><li><a class="nounderline abstract_t">Tishler RB, Loeffler JS, Lunsford LD, et al. Tolerance of cranial nerves of the cavernous sinus to radiosurgery. Int J Radiat Oncol Biol Phys 1993; 27:215.</a></li><li><a class="nounderline abstract_t">Mayo C, Martel MK, Marks LB, et al. Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys 2010; 76:S28.</a></li><li><a class="nounderline abstract_t">Parsons JT, Bova FJ, Fitzgerald CR, et al. Radiation optic neuropathy after megavoltage external-beam irradiation: analysis of time-dose factors. Int J Radiat Oncol Biol Phys 1994; 30:755.</a></li><li><a class="nounderline abstract_t">Cifarelli CP, Schlesinger DJ, Sheehan JP. Cranial nerve dysfunction following Gamma Knife surgery for pituitary adenomas: long-term incidence and risk factors. J Neurosurg 2012; 116:1304.</a></li><li><a class="nounderline abstract_t">Sattler MG, Vroomen PC, Sluiter WJ, et al. Incidence, causative mechanisms, and anatomic localization of stroke in pituitary adenoma patients treated with postoperative radiation therapy versus surgery alone. Int J Radiat Oncol Biol Phys 2013; 87:53.</a></li></ol></div><div id="topicVersionRevision">Topic 86684 Version 11.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9806517" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Initial clinical results of LINAC-based stereotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9609294" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15871511" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20540596" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17218730" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Gamma knife radiosurgery is a successful adjunctive treatment in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17542527" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20460423" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19302582" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The natural history of surgically treated but radiotherapy-naïve nonfunctioning pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18312100" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12780754" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18377253" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18413424" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17197121" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18029107" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16776330" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Gamma surgery in the treatment of nonsecretory pituitary macroadenoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17676409" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Gamma knife radiosurgery for endocrine-inactive pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19900729" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Radiotherapy for pituitary adenomas: long-term efficacy and toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16257131" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Fractionated proton beam irradiation of pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15665560" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The efficacy of linear accelerator radiosurgery in the management of patients with Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17564168" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Gamma Knife surgery for Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8988897" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17356896" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Long-term follow-up results of postoperative radiation therapy for Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25194666" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Outcomes of proton therapy for patients with functional pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21525155" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Radiation therapy in the management of pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16894526" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Linear accelerator radiosurgery for pituitary macroadenomas: a 7-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16649981" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Gamma knife radiosurgery for acromegaly--long-term experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16403824" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17318438" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Treatment of acromegaly: is there still a place for radiotherapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17273921" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Efficacy and safety of CyberKnife radiosurgery for acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11061538" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16883166" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Gamma knife radiosurgery for medically and surgically refractory prolactinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19509108" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Long-term results of stereotactic radiosurgery in secretory pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18710463" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Use of the Leksell gamma knife in the treatment of prolactinoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11143223" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Gamma knife radiosurgery as a primary treatment for prolactinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8961367" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Role of radiation therapy in clinical hormonally-active pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11240250" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hypothalamic/pituitary function following high-dose conformal radiotherapy to the base of skull: demonstration of a dose-effect relationship using dose-volume histogram analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20559089" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Factors associated with endocrine deficits after stereotactic radiosurgery of pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8334743" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8407394" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Tolerance of cranial nerves of the cavernous sinus to radiosurgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20171514" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Radiation dose-volume effects of optic nerves and chiasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7960976" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Radiation optic neuropathy after megavoltage external-beam irradiation: analysis of time-dose factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22424563" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cranial nerve dysfunction following Gamma Knife surgery for pituitary adenomas: long-term incidence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23920387" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Incidence, causative mechanisms, and anatomic localization of stroke in pituitary adenoma patients treated with postoperative radiation therapy versus surgery alone.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
